The free dividend tracker to help you grow your wealth. Link your brokerage accounts and MerryDiv automatically syncs your holdings and dividends.
Data last updated: Sep 06, 2026
Snapshot (as of Sep 06, 2026): AstraZeneca PLC (AZNCF) pays a $3.23 annual dividend ($0.81 quarterly), yielding 1.70% at $189.90/share. Next ex-dividend date 2026-08-07. Source: Yahoo Finance, aggregated by MerryDiv.
Dividend Yield: 1.70%
Annual Dividend: $3.23 per share
Payout Ratio: 49.1%
Ex-Dividend Date: 2026-08-07
Dividend Frequency: quarterly
Sector: Healthcare
Years of Dividend History: 18
AstraZeneca PLC dividend income comes from one of the world's largest biopharmaceutical companies, spanning oncology drugs like Tagrisso and Calquence to cardiovascular therapies like Farxiga. The current yield stands at 1.7%, with a trailing annual dividend rate of $3.23 per share paid quarterly. The next ex-dividend date is August 7, 2026. With a beta of 0.192, AZNCF stock moves far less than the broader market, which suits income investors who prioritize low volatility over high yield.
AstraZeneca PLC pays out 49.1% of earnings as dividends, a payout ratio classified as moderate (40–60%). That level leaves a meaningful buffer, supported by a broad portfolio of prescription drugs sold across primary and specialty care settings worldwide, from oncology treatments to rare disease therapies. AstraZeneca PLC dividend safety faces its clearest pressure from the dividend's own history: the per-share amount in 2025 ($2.615) sat below 2012 levels, showing that currency fluctuations or earnings swings have pushed the dollar-denominated payout lower in past years.
AstraZeneca PLC dividend history shows a CAGR of -1.0% per year from 2011 to 2025. Per-share payments moved from $3.00 at the start of the window to $2.615 by 2025 (with 2026 partial and excluded from this calculation). The largest annual increase in the window was 3.6% in 2022, but the history also contains at least one year-over-year decline exceeding 5%, which explains why the long-run CAGR turned negative. Growth is slow, and on a dollar basis, it has gone backward.
| Period | CAGR | From | To |
|---|---|---|---|
| 3-Year | -3.4% | $2.90 (2022) | $2.62 (2025) |
| 5-Year | -1.4% | $2.80 (2020) | $2.62 (2025) |
| 10-Year | -0.8% | $2.83 (2015) | $2.62 (2025) |
AZNCF stock fits dividend investors who want low market sensitivity and a mid-range payout ratio, not those chasing income maximization. The yield is classified as low (below 2%), and at 1.7% it sits above the 5-year average of 1.49%, so current buyers are getting a slightly better entry yield than the recent norm. The trade-off is real: the dividend has not grown on a consecutive-increase streak, and the 14-year CAGR is negative at -1.0%. What AstraZeneca PLC offers is a globally diversified pharmaceutical business with a payout ratio that leaves room to sustain payments. Income investors accept below-average yield and flat long-run growth in exchange for that low-volatility profile.
| Payment Date | Amount per Share |
|---|---|
| 2026-08-07 | $1.0600 |
| 2026-02-20 | $2.1700 |
| 2025-08-08 | $0.5150 |
| 2025-02-21 | $2.1000 |
| 2024-08-09 | $1.0000 |
| 2024-02-22 | $1.9700 |
| 2023-08-10 | $0.9300 |
| 2023-02-23 | $1.9700 |
| 2022-08-11 | $0.9300 |
| 2022-02-24 | $1.9700 |
| Year | Total Dividends |
|---|---|
| 2026 | $3.2300 |
| 2025 | $2.6150 |
| 2024 | $2.9700 |
| 2023 | $2.9000 |
| 2022 | $2.9000 |
Project income from AZNCF with the AZNCF dividend calculator or track your full portfolio with the dividend tracker.